Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — tnAcity

Breast Cancer Clinical Trial

Official title:
A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.

Clinical Trial Description

ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in women with metastatic triple negative breast cancer.

Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01881230
Study type	Interventional
Source	Celgene
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	September 26, 2013
Completion date	October 28, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03591848` - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility	N/A
Recruiting	`NCT03095352` - A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease	Phase 2
Active, not recruiting	`NCT01472094` - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting	`NCT03544762` - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation	Phase 3
Active, not recruiting	`NCT00341939` - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting	`NCT03709134` - Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
Recruiting	`NCT03667716` - COM701 in Subjects With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03412877` - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer	Phase 2
Active, not recruiting	`NCT02894398` - Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant	Phase 2
Active, not recruiting	`NCT01857193` - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer	Phase 1
Recruiting	`NCT01624090` - Mithramycin for Lung, Esophagus, and Other Chest Cancers	Phase 2
Recruiting	`NCT03432429` - REI-EXCISE iKnife Study	N/A
Active, not recruiting	`NCT02139358` - Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT03615573` - Survey Study: Financial Impact of Breast Cancer Treatment
Active, not recruiting	`NCT02295059` - Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention	N/A
Completed	`NCT03323333` - Psychosocial Intervention Pilot for Partners in BRCA Testing	N/A
Terminated	`NCT01649258` - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy	Phase 1
Withdrawn	`NCT03285607` - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer	Phase 1
Completed	`NCT03384511` - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Phase 4
Recruiting	`NCT01992432` - Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)